ZA200502247B - Selected CGRP antagonists, method for production and use thereof as medicament. - Google Patents

Selected CGRP antagonists, method for production and use thereof as medicament.

Info

Publication number: ZA200502247B
Authority: ZA; South Africa
Prior art keywords: medicament; production; cgrp antagonists; selected cgrp; antagonists
Prior art date: 2002-10-25

Application number

ZA200502247A

Other languages

English (en)

Inventor

Klaus Rudolf

Dirk Stenkamp

Alexander Dreyer

Marcus Schindler

Henri Doods

Mueller Stephan Georg

Philipp Lustenberger

Eckhart Bauer

Kirsten Arndt

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-25

Filing date

2005-03-17

Publication date

2005-09-19

2005-03-17 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2005-09-19 Publication of ZA200502247B publication Critical patent/ZA200502247B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Dermatology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Toxicology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)

ZA200502247A 2002-10-25 2005-03-17 Selected CGRP antagonists, method for production and use thereof as medicament. ZA200502247B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10250082A DE10250082A1 (de)	2002-10-25	2002-10-25	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Publications (1)

Publication Number	Publication Date
ZA200502247B true ZA200502247B (en)	2005-09-19

Family

ID=32103088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200502247A ZA200502247B (en)	2002-10-25	2005-03-17	Selected CGRP antagonists, method for production and use thereof as medicament.

Country Status (25)

Country	Link
US (3)	US20040132716A1 (xx)
EP (1)	EP1558601A1 (xx)
JP (1)	JP4435687B2 (xx)
KR (1)	KR20050083821A (xx)
CN (1)	CN1708492A (xx)
AR (1)	AR043056A1 (xx)
AU (1)	AU2003276157A1 (xx)
BR (1)	BR0315642A (xx)
CA (1)	CA2503462A1 (xx)
CO (1)	CO5570703A2 (xx)
DE (1)	DE10250082A1 (xx)
EA (1)	EA009984B1 (xx)
EC (1)	ECSP055746A (xx)
HR (1)	HRP20050365A2 (xx)
ME (1)	MEP51408A (xx)
MX (1)	MXPA05004188A (xx)
NO (1)	NO20052493L (xx)
PE (1)	PE20040780A1 (xx)
PL (1)	PL376373A1 (xx)
RS (1)	RS20050329A (xx)
TW (1)	TW200427681A (xx)
UA (1)	UA82206C2 (xx)
UY (1)	UY28040A1 (xx)
WO (1)	WO2004037811A1 (xx)
ZA (1)	ZA200502247B (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10163595A1 (de) *	2001-12-21	2003-08-07	Gruenenthal Gmbh	In 3-Position heterocyclisch substituierte Piperidin-2,6-dione
CN100558728C (zh) *	2002-06-05	2009-11-11	布里斯托尔-迈尔斯斯奎布公司	降钙素基因相关肽受体拮抗剂
US7842808B2 (en) *	2002-06-05	2010-11-30	Bristol-Myers Squibb Company	Anti-migraine spirocycles
US7220862B2 (en) *	2002-06-05	2007-05-22	Bristol-Myers Squibb Company	Calcitonin gene related peptide receptor antagonists
US7595312B2 (en) *	2002-10-25	2009-09-29	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
US7569578B2 (en) *	2003-12-05	2009-08-04	Bristol-Meyers Squibb Company	Heterocyclic anti-migraine agents
DE102004015723A1 (de) *	2004-03-29	2005-10-20	Boehringer Ingelheim Pharma	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
TW200533398A (en) *	2004-03-29	2005-10-16	Bristol Myers Squibb Co	Novel therapeutic agents for the treatment of migraine
US20050282857A1 (en) *	2004-04-15	2005-12-22	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018795A1 (de) *	2004-04-15	2005-10-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en)	2004-04-22	2010-04-13	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US20050267141A1 (en) *	2004-05-28	2005-12-01	Phytogen Life Sciences Inc.	Process to prepare camptothecin derivatives
CN101072771B (zh) *	2004-10-07	2010-09-29	默沙东公司	Cgrp受体拮抗剂
WO2006044449A2 (en) *	2004-10-14	2006-04-27	Merck & Co., Inc.	Cgrp receptor antagonists
CA2584241A1 (en) *	2004-10-22	2006-05-04	Merck & Co., Inc.	Cgrp receptor antagonists
US7384930B2 (en) *	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) *	2004-11-03	2008-06-10	Bristol-Myers Squibb Company	Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) *	2004-12-03	2008-11-11	Bristol-Myers Squibb Company	Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
DE102004063752A1 (de) *	2004-12-29	2006-07-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
DE102004063753A1 (de) *	2004-12-29	2006-07-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE102004063755A1 (de) *	2004-12-29	2006-07-20	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
US7491717B2 (en) *	2005-03-23	2009-02-17	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
CN101146799A (zh) *	2005-03-23	2008-03-19	贝林格尔·英格海姆国际有限公司	Cgrp拮抗剂、其制备方法以及其作为药物的用途
EP1770091A1 (de) *	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7439237B2 (en) *	2005-04-15	2008-10-21	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de) *	2005-08-17	2007-02-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7834007B2 (en) *	2005-08-25	2010-11-16	Bristol-Myers Squibb Company	CGRP antagonists
EP1770086A1 (de) *	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
DE102005050892A1 (de) *	2005-10-21	2007-04-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
KR20080068062A (ko)	2005-11-14	2008-07-22	리나트 뉴로사이언스 코퍼레이션	칼시토닌 유전자-관련 펩티드에 대해 지시되는 길항제 항체및 그의 사용 방법
DE102006017827A1 (de) *	2006-04-13	2007-10-18	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue kristalline Verbindungen
PE20080370A1 (es) *	2006-06-08	2008-06-13	Boehringer Ingelheim Int	Derivados de quinazolinona como antagonistas de cgrp
JP5335228B2 (ja) *	2006-12-27	2013-11-06	キヤノン株式会社	新規化合物および有機半導体素子の製造方法
EA201000612A1 (ru)	2007-10-18	2010-10-29	Бёрингер Ингельхайм Интернациональ Гмбх	Антагонисты cgrp-пептиды
EP2065381A1 (de)	2007-10-18	2009-06-03	Boehringer Ingelheim Pharma GmbH & Co. KG	CGRP Antagonisten
EP2225223B1 (de)	2007-11-22	2017-01-11	Boehringer Ingelheim International GmbH	Organische verbindungen
BRPI0908276B8 (pt)	2008-03-04	2021-05-25	Labrys Biologics Inc	uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
ES2689322T3 (es)	2008-03-04	2018-11-13	Teva Pharmaceuticals International Gmbh	Métodos para tratar el dolor crónico
RU2535074C2 (ru)	2009-08-28	2014-12-10	Лэйбрис Байолоджикс, Инк.	Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
US9745373B2 (en)	2011-05-20	2017-08-29	Alderbio Holdings Llc	Anti-CGRP compositions and use thereof
SG194973A1 (en)	2011-05-20	2013-12-30	Alderbio Holdings Llc	Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
AU2012258976B8 (en)	2011-05-20	2017-07-20	H. Lundbeck A/S	Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
WO2016199688A1 (ja) *	2015-06-10	2016-12-15	住友化学株式会社	カーバメート化合物の製造方法
GB201519196D0 (en) *	2015-10-30	2015-12-16	Heptares Therapeutics Ltd	CGRP Receptor Antagonists
AU2020206241A1 (en)	2019-01-08	2021-08-26	H. Lundbeck A/S	Acute treatment and rapid treatment of headache using anti-CGRP antibodies
KR20210124867A (ko)	2020-04-06	2021-10-15	하. 룬드벡 아크티에셀스카브	항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
CN113655035B (zh) *	2021-08-12	2024-06-28	深圳上泰生物工程有限公司	一种糖缺失性转铁蛋白分离方法及检测方法与试剂盒

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US665378A (en) *	1900-06-15	1901-01-01	William James Mcmurtry	Manufacture of self-igniting gas mediums.
TW209870B (xx) *	1990-01-18	1993-07-21	Pfizer
US5442044A (en) *	1991-01-04	1995-08-15	Pfizer Inc.	Orally active renin inhibitors
DK0927192T3 (da)	1996-09-10	2004-09-13	Boehringer Ingelheim Pharma	Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling
DE19911039A1 (de) *	1999-03-12	2000-09-14	Boehringer Ingelheim Pharma	Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6653478B2 (en) *	2000-10-27	2003-11-25	Ortho-Mcneil Pharmaceutical, Inc.	Substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
CN100558728C (zh) *	2002-06-05	2009-11-11	布里斯托尔-迈尔斯斯奎布公司	降钙素基因相关肽受体拮抗剂
DE10300973A1 (de) *	2003-01-14	2004-07-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO2005084672A1 (de)	2004-03-03	2005-09-15	Boehringer Ingelheim International Gmbh	Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE102004015723A1 (de) *	2004-03-29	2005-10-20	Boehringer Ingelheim Pharma	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018795A1 (de)	2004-04-15	2005-10-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7547694B2 (en) *	2004-04-15	2009-06-16	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de)	2004-04-15	2005-10-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) *	2004-04-15	2007-10-09	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7696195B2 (en) *	2004-04-22	2010-04-13	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004019492A1 (de)	2004-04-22	2005-11-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770091A1 (de) *	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7491717B2 (en) *	2005-03-23	2009-02-17	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
CN101146799A (zh)	2005-03-23	2008-03-19	贝林格尔·英格海姆国际有限公司	Cgrp拮抗剂、其制备方法以及其作为药物的用途
US7439237B2 (en) *	2005-04-15	2008-10-21	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (de)	2005-08-17	2007-02-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770087A1 (de)	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) *	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005050892A1 (de)	2005-10-21	2007-04-26	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

2002
- 2002-10-25 DE DE10250082A patent/DE10250082A1/de not_active Withdrawn
2003
- 2003-10-15 US US10/685,921 patent/US20040132716A1/en not_active Abandoned
- 2003-10-23 UA UAA200504875A patent/UA82206C2/uk unknown
- 2003-10-23 KR KR1020057007157A patent/KR20050083821A/ko not_active Withdrawn
- 2003-10-23 WO PCT/EP2003/011763 patent/WO2004037811A1/de not_active Ceased
- 2003-10-23 JP JP2004545964A patent/JP4435687B2/ja not_active Expired - Fee Related
- 2003-10-23 AU AU2003276157A patent/AU2003276157A1/en not_active Abandoned
- 2003-10-23 CN CNA2003801019804A patent/CN1708492A/zh active Pending
- 2003-10-23 BR BR0315642-7A patent/BR0315642A/pt not_active IP Right Cessation
- 2003-10-23 EP EP03809318A patent/EP1558601A1/de not_active Withdrawn
- 2003-10-23 PE PE2003001078A patent/PE20040780A1/es not_active Application Discontinuation
- 2003-10-23 EA EA200500601A patent/EA009984B1/ru not_active IP Right Cessation
- 2003-10-23 ME MEP-514/08A patent/MEP51408A/xx unknown
- 2003-10-23 CA CA002503462A patent/CA2503462A1/en not_active Abandoned
- 2003-10-23 PL PL03376373A patent/PL376373A1/xx not_active Application Discontinuation
- 2003-10-23 RS YUP-2005/0329A patent/RS20050329A/sr unknown
- 2003-10-23 HR HR20050365A patent/HRP20050365A2/hr not_active Application Discontinuation
- 2003-10-23 MX MXPA05004188A patent/MXPA05004188A/es unknown
- 2003-10-24 AR ARP030103890A patent/AR043056A1/es unknown
- 2003-10-24 TW TW092129585A patent/TW200427681A/zh unknown
- 2003-10-24 UY UY28040A patent/UY28040A1/es not_active Application Discontinuation
2005
- 2005-03-17 ZA ZA200502247A patent/ZA200502247B/xx unknown
- 2005-04-25 EC EC2005005746A patent/ECSP055746A/es unknown
- 2005-05-24 NO NO20052493A patent/NO20052493L/no not_active Application Discontinuation
- 2005-05-24 CO CO05050510A patent/CO5570703A2/es not_active Application Discontinuation
2007
- 2007-06-04 US US11/757,743 patent/US7700589B2/en not_active Expired - Lifetime
2010
- 2010-02-17 US US12/706,840 patent/US20100152171A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE10250082A1 (de)	2004-05-13
UA82206C2 (uk)	2008-03-25
EA200500601A1 (ru)	2006-02-24
UY28040A1 (es)	2004-05-31
NO20052493D0 (no)	2005-05-24
TW200427681A (en)	2004-12-16
MXPA05004188A (es)	2005-10-05
WO2004037811A1 (de)	2004-05-06
CA2503462A1 (en)	2004-05-06
JP4435687B2 (ja)	2010-03-24
CO5570703A2 (es)	2005-10-31
ECSP055746A (es)	2005-07-06
HRP20050365A2 (en)	2006-05-31
EA009984B1 (ru)	2008-04-28
MEP51408A (en)	2011-02-10
EP1558601A1 (de)	2005-08-03
US20070244099A1 (en)	2007-10-18
AR043056A1 (es)	2005-07-13
RS20050329A (sr)	2007-08-03
NO20052493L (no)	2005-05-24
KR20050083821A (ko)	2005-08-26
PL376373A1 (en)	2005-12-27
CN1708492A (zh)	2005-12-14
BR0315642A (pt)	2005-08-30
AU2003276157A1 (en)	2004-05-13
US20100152171A1 (en)	2010-06-17
US20040132716A1 (en)	2004-07-08
PE20040780A1 (es)	2005-01-14
JP2006505573A (ja)	2006-02-16
US7700589B2 (en)	2010-04-20
WO2004037811A8 (de)	2005-05-19

Publication	Publication Date	Title
ZA200502247B (en)	2005-09-19	Selected CGRP antagonists, method for production and use thereof as medicament.
IL168056A0 (en)	2009-02-11	Selected cgrp antagonists, method for production and use thereof as medicament
ZA200705879B (en)	2009-01-28	CGRP antagonists, method for production thereof, and their use as medicaments
IL186090A0 (en)	2008-01-20	Cgrp antagonists, method for the production thereof, and their use as medicaments
PL378065A1 (pl)	2006-02-20	Podstawione związki N-aryloheterocykliczne, sposób ich wytwarzania oraz ich zastosowanie jako środków leczniczych
AU2003265853A8 (en)	2004-03-19	Hedgehog antagonists, methods and uses related thereto
IL181012A0 (en)	2007-07-04	Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
IL190423A0 (en)	2008-11-03	Selected cgrp antagonists , methods for the production thereof and their use as medicaments
IL174952A0 (en)	2006-08-20	Sulfoximine-substituted pyrimidines for use as cdk and/or vegf inhibitors, the production thereof and their use as drugs
AU2003257465A1 (en)	2004-02-23	Substituted diaryl heterocycles, method for the production and use thereof as medicaments
IL180874A0 (en)	2007-07-04	Substituted, bicyclic 8-pyrrolidinoxanthines, method for the production thereof and their use as medicaments
IL168102A0 (en)	2009-02-11	Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
IL162669A0 (en)	2005-11-20	Antichlinergic agents, method for producing the same and use thereof as medicaments
IL189497A0 (en)	2008-08-07	Selected cgrp antagonists, methods for the production thereof and their use as medicaments
MXPA02004119A (es)	2003-10-06	Nuevos ciclopropanos como antagonistas de cgrp, medicamentos que contienen estos compuestos y metodo para obtencion de los mismos.
IL162316A0 (en)	2005-11-20	Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition t
PL376399A1 (en)	2005-12-27	Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
PL371784A1 (en)	2005-06-27	Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
ZA200407361B (en)	2006-02-22	Acyl-3-carboxyphenylurea derivatives, method for production and use thereof.
ZA200409095B (en)	2005-05-10	Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same.
IL169318A0 (en)	2009-02-11	Pyrimidines, methods for the production thereof, and use thereof
IL174975A0 (en)	2006-08-20	2-phenyl-benzofuran derivatives, method for the production thereof and their use
ZA200601001B (en)	2007-03-28	Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicament comprising the same
IL162562A0 (en)	2005-11-20	Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolid
MXPA03007550A (es)	2003-12-04	Derivados coloporosidos, proceso para su preparacion y su uso.